Imrecoxib: Advances in Pharmacology and Therapeutics DOI Creative Commons
Yanhong Wang, Lingling Zhu,

Tianlang Li

и другие.

Drug Design Development and Therapy, Год журнала: 2024, Номер Volume 18, С. 1711 - 1725

Опубликована: Май 1, 2024

Abstract: Imrecoxib, a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID), was discovered via the balanced inhibition strategy of COX-1/COX-2. It is indicated for relief painful symptoms osteoarthritis. There have been some pharmacological and therapeutic advances since approval imrecoxib in 2011. However, an update review this aspect not yet available. Relevant literature until January 2024 identified by search PubMed, Web science, Embase CNKI. From perspective efficacy, provides osteoarthritis symptoms, potential off-label use treatment idiopathic pulmonary fibrosis, perioperative pain, hand-foot syndrome, axial spondyloarthritis, COVID-19, cartilage injury, malignancies such as lung colon cancer. safety point view, showed adverse effects common to NSAIDs; however, it has lower incidence new-onset hypertension than other types COX-2 inhibitors, less gastrointestinal toxicities non-selective NSAIDs, weaker risk interaction celecoxib, more suitable elderly patients due pharmacoeconomic perspective, cost-effective celecoxib diclofenac patients. With deepening disease pathophysiology study osteoarthritis, new schemes mechanisms are constantly discovered. In field treatment, analgesic inhibitors also being explored. Taken together, moderate inhibitor with advantages, there would be clinical applications research opportunities future. Keywords: cyclooxygenase-2, imrecoxib, drug, older adults,

Язык: Английский

Imrecoxib: Advances in Pharmacology and Therapeutics DOI Creative Commons
Yanhong Wang, Lingling Zhu,

Tianlang Li

и другие.

Drug Design Development and Therapy, Год журнала: 2024, Номер Volume 18, С. 1711 - 1725

Опубликована: Май 1, 2024

Abstract: Imrecoxib, a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID), was discovered via the balanced inhibition strategy of COX-1/COX-2. It is indicated for relief painful symptoms osteoarthritis. There have been some pharmacological and therapeutic advances since approval imrecoxib in 2011. However, an update review this aspect not yet available. Relevant literature until January 2024 identified by search PubMed, Web science, Embase CNKI. From perspective efficacy, provides osteoarthritis symptoms, potential off-label use treatment idiopathic pulmonary fibrosis, perioperative pain, hand-foot syndrome, axial spondyloarthritis, COVID-19, cartilage injury, malignancies such as lung colon cancer. safety point view, showed adverse effects common to NSAIDs; however, it has lower incidence new-onset hypertension than other types COX-2 inhibitors, less gastrointestinal toxicities non-selective NSAIDs, weaker risk interaction celecoxib, more suitable elderly patients due pharmacoeconomic perspective, cost-effective celecoxib diclofenac patients. With deepening disease pathophysiology study osteoarthritis, new schemes mechanisms are constantly discovered. In field treatment, analgesic inhibitors also being explored. Taken together, moderate inhibitor with advantages, there would be clinical applications research opportunities future. Keywords: cyclooxygenase-2, imrecoxib, drug, older adults,

Язык: Английский

Процитировано

1